News

BioSpace2h
GSK’s Blenrep Loses Adcomm Vote, Further Clouding Comeback Bid
The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...
STAT2h
Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
pharmaphorum5h
GSK's growth plans dented by Blenrep setback
The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...
Health Care Roundup: Market Talk
Find insight on GSK, Novartis , Sarepta Therapeutics and more in the latest Market Talks covering Health Care.
Fierce Pharma3d
As GSK eyes Blenrep's US return, FDA flags eye safety concerns ahead of advisory committee meeting
GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...
FTSE 100 Live 18 July: Reckitt Benckiser sells Cillit Bang, GSK shares slide
A setback for GSK after one of its late-stage pipeline assets failed to win the support of a US panel today triggered a 6% ...
Global Stocks in the Spotlight: Alibaba, Saab, Burberry, GSK
The Swedish defense company posted better-than-expected earnings and [raised its annual sales guidance]( ...
FDA votes against overall benefit/risk profile of GSK's multiple myeloma candidate at proposed dosage
Drugmaker GSK said on Friday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had voted against ...